Find Clinical Trials

Back My cancer has not gone away or has come back Cancer progressed on treatment

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

I want to enter information about my genetic testing (e.g, BRCA) and/or tumor testing results

I want to filter the trials based on location, phase of development, or drug name, category or target

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

III

Recurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy)

ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

CO, GA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Rucaparib	AG-014699, PF 01367338, CO-338, Rubraca	PARP inhibitor	Approved in Ovarian Cancer

III

Platinum resistant or refractory ovarian cancer, excluding primary platinum refractory

A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

AL, AZ, CA, CT, FL, GA, IL, IN, KS, KY, LA, MD, MA, MI, NH, NJ, NM, NY, NC, ND, OH, OK, PA, SC, SD, TN, TX, VT, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ofranergene Obadenovec	VB-111	Endothelin promoter-apoptotic receptor gene therapy	Clinical Trials
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

III

Recurrent ovarian cancer

Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Platinum-Resistant or -Sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

MS, WV

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent	Approved in Ovarian Cancer
Docetaxel	Taxotere	Microtubule stabilizer/mitotic inhibitor	Approved in Other Cancers
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Topotecan	Hycamptamine, Hycamtin, TOPO	Topoisomerase I inhibitor	Approved in Ovarian Cancer

III

Platinum resistant ovarian cancer

Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

AZ, CA, LA, OH, OK, PA, WV

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent	Approved in Ovarian Cancer
Docetaxel	Taxotere	Microtubule stabilizer/mitotic inhibitor	Approved in Other Cancers
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Topotecan	Hycamptamine, Hycamtin, TOPO	Topoisomerase I inhibitor	Approved in Ovarian Cancer

III

Recurrent ovarian cancer, excluding primary platinum refractory

ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer

AZ, CA, CO, FL, GA, IA, KY, MD, MA, MN, MO, NE, NV, NJ, NC, OH, OR, PA, RI, SD, TX, VA, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
TTfields	NovoTTF-100L(O)	Microtubule destabilizer/mitotic inhibitor	Clinical Trials

III

Platinum resistant or refractory FRalpha+ high grade serous ovarian cancer, excluding primary platinum refractory

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

AZ, CA, CO, FL, GA, IL, KY, LA, MD, MA, MI, MN, MO, MT, NV, NJ, NC, OH, OK, OR, PA, RI, TN, TX, VA, WA, WV

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Mirvetuximab Soravtansine	Anti-FOLR1-mab Maytansinoid Conjugate, IMGN853, M9346A-sulfo-SPDB-DM4	ADC: anti-FOLR1 + microtubule destabilizer (DM4)	Clinical Trials

III

Platinum resistant or refractory FRalpha+ ovarian cancer with prior bevacizumab, excluding primary platinum refractory

SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

AZ, CA, FL, IL, MD, MA, MO, NJ, TN, TX, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Mirvetuximab Soravtansine	Anti-FOLR1-mab Maytansinoid Conjugate, IMGN853, M9346A-sulfo-SPDB-DM4	ADC: anti-FOLR1 + microtubule destabilizer (DM4)	Clinical Trials

IIa

Recurrent ovarian cancer

A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

CA, FL, LA, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Anlotinib	Catequentinib, AL3818	VEGFR2/3 kinase inhibitor	Clinical Trials
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

IIa

Platinum resistant or refractory ovarian cancer with BRCA1/2 mutations

A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies

CA, CO, MA, OR, PA, SC

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
BMS-986158	BET inhibitor BMS-986158	BET inhibitor	Clinical Trials
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II/III

Platinum resistant or refractory high grade serous or endometrioid ovarian cancer or germline BRCA1/2-mutated ovarian cancer

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

AL, AK, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cediranib	AZD2171, Cediranib maleate, Recentin	VEGFR1-3 kinase inhibitor	Clinical Trials
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer

II/III

Platinum resistant or refractory ovarian cancer

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer

AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, VA, WA, WV, WI, WY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer

II

Platinum resistant or refractory ovarian cancer

Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers

AZ, FL, MN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Topotecan	Hycamptamine, Hycamtin, TOPO	Topoisomerase I inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with FGFR1-4, PDGFRa, Kit, RET, FLT3, or Abl1 alterations

Phase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1)

OH

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ponatinib	multitargeted tyrosine kinase inhibitor AP24534, Iclusig, AP24534	Multi-targeted kinase inhibitor	Approved in Other Cancers

II

Advanced solid tumors with KRAS or NRAS mutations (in expansion)

An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid Tumors

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Navitoclax	ABT-263, A-855071.0, Bcl-2 Family Protein Inhibitor ABT-263	Bcl-2, Bcl-XL, and Bcl-w inhibitor	Clinical Trials
Trametinib	Mekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212	MEK1/2 inhibitor	Approved in Other Cancers

II

Recurrent ovarian cancer with germline BRCA1/2 mutations (no prior anti-CTLA-4 mAb)

A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer

FL, NM, OH, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer
Tremelimumab	anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab	Blocks CTLA-4 inhibition of T cells	Clinical Trials

II

Advanced solid tumors with NTRK1/2/3, ROS1, or ALK rearrangements

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

AZ, CA, CO, CT, DC, FL, GA, IL, MD, MA, MI, MN, MO, NV, NY, NC, OH, OR, TX, UT, VA, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Entrectinib	TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RXDX-101	ALK, TRK, ROS1 kinase inhibitor	Approved in Other Cancers

II

Ovarian expansion for BRCA1/2 MUT, or CDKN2A loss or MUT, or high TMB, or ERBB2 AMP, MUT or over-expression or Advanced solid tumors with molecular alterations in AKT1, ALK, ATM, BRAF, BRAFV600E/D/K/R, BRCA1/2, CDK4, CDK6, CDKN2A, CSF1R, FGFR1-3, FLT-3, KIT, MET, MLH1, MSH2, MSH6, mTOR, PALB2, PDGFR, PDGFRB, PMS2, POLD1, POLE, RAF-1, RET, ROS1, TSC1/2, VEGFR, high MSI, high TMB

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

AL, AZ, CA, FL, GA, HI, IL, IN, MI, NE, NC, ND, OK, OR, PA, SD, TX, UT, VA, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Afatinib	BIBW 2992 MA2, Gilotrif, Afatinib dimaleate	EGFR, HER2, HER4 kinase inhibitor	Approved in Other Cancers
Cobimetinib	XL518, GDC-0973, Cotellic	MEK1 inhibitor	Approved in Other Cancers
Crizotinib	c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori	c-Met and ALK kinase inhibitor	Approved in Other Cancers
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer
Palbociclib	PD-0332991, PD0332991, Ibrance	CDK4/6 inhibitor	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Pertuzumab	Perjeta, monoclonal antibody 2C4, rhuMAb2C4	HER2 dimerization inhibitor	Approved in Other Cancers
Regorafanib	BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga	Multi-targeted RTK inhibitor	Approved in Other Cancers
Sunitinib	Sutent, Sunitinib malate	VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit	Approved in Other Cancers
Talazoparib	Talazoparib Tosylate, BMN-673, MDV3800	PARP inhibitor	Approved in Other Cancers
Temsirolimus	Torisel, CCI-779	mTOR inhibitor	Approved in Other Cancers
Trastuzumab	Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody	HER2 antagonist	Approved in Other Cancers
Vemurafenib	RO5185426, PLX4032, Zelboraf	BRAF kinase inhibitor	Approved in Other Cancers

II

Advanced solid tumors with alterations in AKT, cKIT, CDK4/6 AMP, EGFR, MET, MET AMP, mTOR, NTRK1-3, PTCH1, PTEN, SMO, TSC1/2

Molecular Analysis for Therapy Choice (MATCH)

AL, AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, WY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Afatinib	BIBW 2992 MA2, Gilotrif, Afatinib dimaleate	EGFR, HER2, HER4 kinase inhibitor	Approved in Other Cancers
Copanlisib	BAY 80-6946, PI3K inhibitor BAY 80-6946	pan-PI3K inhibitor	Approved in Other Cancers
Crizotinib	c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori	c-Met and ALK kinase inhibitor	Approved in Other Cancers
Ipatasertib	GDC-0068, Akt Inhibitor GDC-0068, RG7440	pan-AKT inhibitor	Clinical Trials
Larotrectinib	LOXO-101, Trk inhibitor LOXO-101	pan-Trk kinase inhibitor	Approved in Other Cancers
Palbociclib	PD-0332991, PD0332991, Ibrance	CDK4/6 inhibitor	Approved in Other Cancers
Sapanisertib	TAK-228, MLN0128, TORC1/2 Inhibitor MLN0128, TORC1/2 Inhibitor INK128, INK128	TORC1/2 kinase inhibitor	Clinical Trials
Sunitinib	Sutent, Sunitinib malate	VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit	Approved in Other Cancers
Vismodegib	Hedgehog antagonist GDC-0449, Erivedge, GDC-0449	Smoothened antagonist	Approved in Other Cancers

II

Advanced solid tumors with high MSI or high TMB

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)

CA, CO, FL, MD, MA, NJ, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors (in ovarian expansion) - intratumoral injection

A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies

CA, DC, FL, IA, MI, NY, RI, SD, TX, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Avelumab	Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
PD-0360324	anti–M-CSF mAb PD-0360324, anti-CSF1 monoclonal antibody PD-0360324	CSF1R antagonist and tumor-associated macrophage inhibitor	Clinical Trials

II

Partially platinum sensitive, resistant or refractory ovarian cancer, excluding primary platinum refractory (for combo w/ rucaparib patients have to be BRCA WT)

A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Rucaparib	AG-014699, PF 01367338, CO-338, Rubraca	PARP inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors and granulosa cell ovarian cancer (in expansion)

A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Methoxyamine	TRC102	Base excision repair inhibitor	Clinical Trials
Temozolomide	Temodal, Temodar, Methazolastone	DNA damaging agent	Approved in Other Cancers

II

Platinum resistant, refractory or persistent ovarian cancer (no measurable disease outside the peritoneal cavity)

A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer

AZ, FL, MN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
MV-NIS	oncolytic measles virus encoding thyroidal sodium iodide symporter	Induces immune response and tumor cell lysis	Clinical Trials

II

Advanced ovarian small cell cancer

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

AL, AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, WY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with lesion treatable with radiation therapy

Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Radiation Therapy	Radiotherapy, Irradiation

II

Platinum resistant or refractory clear cell ovarian cancer

Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Tremelimumab	anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab	Blocks CTLA-4 inhibition of T cells	Clinical Trials

II

Platinum resistant ovarian cancer

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
p53MVA	Modified Vaccinia Virus Ankara Vaccine Expressing p53, MVAp53	Immune response against p53 tumor antigen	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with IDH1 or IDH2 mutations

A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors

CA, CT, FL, GA, KY, MD, MA, MO, NJ, NC, OH, PA, TN, TX, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors

Evaluating Immune Checkpoint Inhibition In Solid Tumor Patients With Homologous Recombination Repair Deficiency

FL

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with SETD2 deficiency

A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies

CA, IL, KS, MD, MA, MO, PA, TN, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Adavosertib	WEE1 inhibitor AZD1775, MK1775, AZD1775	WEE1 inhibitor	Clinical Trials

II

Advanced solid tumors with CCND1/2/3 alterations or CDK4/6 amplifications

A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers

II

Recurrent clear cell ovarian cancer

BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

RI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
TCR-transduced PBL	autologous PBLs retrovirally-transduced with TCRs targeting neoantigens	Immune response against tumor-associated antigens	Clinical Trials

II

Advanced solid tumors with POLE, POLD, or BRCA1/2 mutations

A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability

NJ

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Recurrent ovarian cancer

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian Cancer

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ceralasertib	AZD6738, ATR kinase inhibitor AZD6738	ATR kinase inhibitor	Clinical Trials
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with CDK12 alterations

IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

CA, FL, MD, MI, MO, NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Recurrent ovarian cancer with progression on or after prior PARP inhibitor

EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition

MA, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Adavosertib	WEE1 inhibitor AZD1775, MK1775, AZD1775	WEE1 inhibitor	Clinical Trials
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer

II

Recurrent or refractory high grade serous ovarian cancer or carcinosarcoma

Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
MDA-TIL	autologous tumor-infiltrating lymphocytes MDA-TIL	Anti-tumor immune response	Clinical Trials

II

Recurrent ovarian cancer with dMMR, high MSI og high TMB

An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer

CA, MA, NY, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with high TMB

A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

CA, CO, MN, NY, NC, OR, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Platinum resistant or refractory mesothelin+ high grade serous or endometroid ovarian cancer

A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer

FL, MO, NJ, OH, TN, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Anetumab ravtansine	Anti-mesothelin Antibody-Drug Conjugate BAY 94-9343, BAY 94-9343	ADC: anti-Mesothelin + microtubule destabilizer (DM4)	Clinical Trials
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with ARID1A or ATM alterations

Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ceralasertib	AZD6738, ATR kinase inhibitor AZD6738	ATR kinase inhibitor	Clinical Trials
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with dMMR, high TMB or high MSI with limited progression on checkpoint inhibitor treatment

A Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint Blockade

CT, NJ, NY, PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Radiation Therapy	Radiotherapy, Irradiation

II

Advanced solid cancer with ATM, BRCA1/2, FBXW7, ARID1A, or HR gene mutations or MYC or CCNE1 amplification

A Phase II Study of M6620 (VX-970) in Selected Solid Tumors

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Berzosertib	ATR kinase inhibitor VX-970, VE-822, M6620, VX-970	ATR kinase inhibitor	Clinical Trials

II

Recurrent ovarian cancer

A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression Profiling

CA, MN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Platinum sensitive ovarian cancer with first or second recurrence in peritoneal cavity

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Rintatolimod	Atvogen	TLR3 agonist and immune cell stimulator	Approved in Other Indications

II

Recurrent low grade serous ovarian cancer

A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum

CA, FL, GA, IL, IN, MN, NH, NJ, NM, OH, OK, PA, RI, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Letrozole	Femara	Aromatase inhibitor	NCCN Guidelines for Ovarian Cancer
Ribociclib	Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali	CDK4/6 inhibitor	Approved in Other Cancers

II

Platinum resistant ovarian cancer without BRCA1/2 mutations, with DNA Damage Repair gene mutations (e.g., ATM, PALB2, RAD51D) or HRD+

A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

AZ, CA, CO, GA, KY, MD, MA, MI, NE, NJ, NY, OK, PA, SD, UT, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer

II

Platinum resistant or refractory ovarian cancer (excluding primary platinum refractory, ≤1 prior therapy for resistant disease)

Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen

CA, CO, FL, GA, KS, MI, MO, NJ, NY, NC, OH, TX, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Tisotumab Vedotin	TF-011-MMAE, HuMax-TF-ADC	ADC: anti-TF + microtubule destabilizer (MMAE)	Clinical Trials

II

Advanced solid tumors (in ovarian expansion)

A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)

CA, FL, NJ, NY, TN, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Lenvatinib	E7080, ER-203492-00, Lenvima, MK-7902	VEGFR1-3 kinase inhibitor	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with ALK or ROS1 activating genomic aberrations

Phase II Study of Brigatinib for Advanced Solid Cancers Harboring Genomic Alterations in ALK (Excluding Lung) and ROS1 Oncogenes

OH

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Brigatinib	AP26113	ALK and EGFR kinase inhibitor	Approved in Other Cancers

II

Recurrent ovarian cancer

Phase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
2X-121	E7449, PARP/Tankyrase inhibitor 2X-121, Stenoparib	PARP inhibitor	Clinical Trials

II

Advanced solid tumors - intratumoral injection

A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

NJ, NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Radiation Therapy	Radiotherapy, Irradiation
Talimogene Laherparepvec	GM-CSF-encoding oncolytic herpes simplex virus, T-VEC	Induces immune response and tumor cell lysis	Approved in Other Cancers

II

Ovarian cancer refractory to first- and second-line therapy

A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin		IL-2 receptor agonist	Approved in Other Cancers
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Young TIL	autologous tumor-infiltrating lymphocytes Young TIL	Immune response against tumor-associated antigens	Clinical Trials

II

Recurrent PR+ low grade serous or granulosa cell ovarian cancer

Basket Study of the Oral Progesterone Antagonist Onapristone ER (Apristor) in Women With Progesterone Receptor Positive (PR+) Recurrent Granulosa Cell Tumor, Low Grade Serous Ovarian Cancer or Endometrioid Endometrial Cancer

NJ, NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Onapristone ER	extended-release onapristone	PR antagonist that blocks PR activation and the associated expression of PR-responsive genes

II

Advanced solid tumors with moderate/high TMB

Phase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

KY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Tremelimumab	anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab	Blocks CTLA-4 inhibition of T cells	Clinical Trials

II

Advanced solid tumors with FGFR1-3 gene mutations or translocations

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

AZ, CA, FL, IL, IN, IA, KS, LA, ME, MA, MN, NV, NH, NJ, NY, NC, OK, SC, TN, TX, VA, WA, WV, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pemigatinib	INCB054828, FGFR inhibitor INCB054828	FGFR1-3 inhibitor	Approved in Other Cancers

II

Advanced solid tumors (with tumor amenable to skin biopsy)

DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (Durvalumab) in Combination With Chemotherapy in Patients With Advanced Solid Tumors

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Capecitabine	Xeloda, CAPE	RNA processing and thymidylate synthase inhibitor	NCCN Guidelines for Ovarian Cancer
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
nab-Paclitaxel	Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007	Microtubule stabilizer/mitotic inhibitor	NCCN Guidelines for Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors

A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin		IL-2 receptor agonist	Approved in Other Cancers
Autologous TILs		Immune response against tumor-associated antigens	Clinical Trials
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers

II

Platinum resistant ovarian cancer without BRCA1/2 mutations with prior bevacizumab

A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)

AZ, CA, FL, IL, IN, IA, LA, MD, MA, MN, MS, NM, NY, NC, OH, OR, PA, RI, TN, TX, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Dostarlimab	ANB011, anti-PD-1 monoclonal antibody TSR-042, TSR-042	Blocks PD-L1/2 inhibition of T cells	Clinical Trials
Niraparib	MK4827, Zejula	PARP inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors (amenable to radiation therapy)

Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Radiation Therapy	Radiotherapy, Irradiation

II

Recurrent high grade serous ovarian cancer or carcinosarcoma

Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin		IL-2 receptor agonist	Approved in Other Cancers
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers
LN-145-S1	Autologous Tumor Infiltrating Lymphocytes LN-145-S1, PD-1 selected TIL therapy	Immune response against tumor-associated antigens	Clinical Trials

II

Advanced solid tumors with brain metastases and NTRK, ROS1, CDK pathway or PI3K pathway alterations

Genomically-Guided Treatment Trial in Brain Metastases

AK, AZ, AR, CA, CO, CT, FL, GA, ID, IL, IA, KY, LA, MA, MI, MN, MS, MO, MT, NE, NH, NJ, NM, NY, NC, OH, OK, OR, PA, TX, UT, VT, VA, WA, WI, WY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Entrectinib	TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RXDX-101	ALK, TRK, ROS1 kinase inhibitor	Approved in Other Cancers
GDC-0084	PI3K inhibitor GDC-0084, RG7666, Paxalisib	PI3K/mTOR inhibitor

II

Advanced solid tumors with NF1, KEAP1/NRF2 or LKB1 mutations

A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors

FL, KY, MD, MA, NY, OH, PA, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Telaglenastat	glutaminase inhibitor CB-839, CD-839	Glutaminase inhibitor	Clinical Trials

II

Advanced solid tumors with FGFR mutations or translocations

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumors Harboring Activating FGFR Mutations or Translocations (FIGHT-208)

CA, FL, HI, IL, MD, NJ, OH, SD, TX, UT

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pemigatinib	INCB054828, FGFR inhibitor INCB054828	FGFR1-3 inhibitor	Approved in Other Cancers

II

Platinum sensitive high grade serous or endometrioid ovarian cancer or BRCA1/2-mutated ovarian cancer

A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer

CA, CO, CT, GA, IL, MO, NM, NY, OH, OK, PA, RI, TX, VA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer
Tremelimumab	anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab	Blocks CTLA-4 inhibition of T cells	Clinical Trials

II

Platinum resistant or refractory ovarian cancer

Phase II Study of ONC201 Plus Weekly Paclitaxel in Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

MI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
ONC201	AKT/ERK inhibitor ONC201, TIC10	AKT and ERK kinase inhibitor	Clinical Trials
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with IDH1 mutations

Phase II Study of IDH1 Inhibitor Ivosidenib and Nivolumab in IDH1 Mutant Gliomas and Advanced Solid Tumors

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ivosidenib	AG-120	IDH1 inhibitor	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with FGFR mutations or gene fusions

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations

AZ, CO, DE, FL, GA, ME, MA, MI, NJ, NY, NC, OH, PA, TN, TX, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Erdafitinib	pan-FGFR tyrosine kinase inhibitor JNJ-42756493	pan-FGFR kinase inhibitor	Approved in Other Cancers

II

Advanced solid tumors with mutations in homologous repair (HRR) genes (i.e. BRIP1, PALPB2 etc.) or HRD+ patients

A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer

AL, AZ, CA, FL, GA, KY, NJ, NY, OH, TX, UT, VA, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Recurrent carcinosarcoma

A Phase II Single Arm Study of Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma

AL

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cabozantinib	BMS-907351, Cabometyx, XL184, Cometriq	Multi-targeted RTK inhibitor	Approved in Other Cancers
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with mutations in BARD1, BRIP1, FANCA, NBN, RAD51, RAD51B, RAD51C or RAD51D

A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes

CA, FL, IL, IA, MA, MN, NY, OH, OK, PA, TN, TX, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Rucaparib	AG-014699, PF 01367338, CO-338, Rubraca	PARP inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with EGFR or ERBB2 activating mutations

A Phase 2 Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Poziotinib	NOV120101, pan-HER kinase inhibitor HM781-36B	EGFR, HER2, HER4 kinase inhibitor

II

Advanced solid tumors with FGFR alterations

A Phase II Study of Oral Infigratinib in Adult Patients With Advanced or Metastatic Solid Tumors With FGFR1-3 Gene Fusions or Other FGFR Genetic Alterations

OH

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Infigratinib	pan FGFR Kinase Inhibitor BGJ398, BGJ398	pan-FGFR kinase inhibitor	Clinical Trials

II

Recurrent platinum sensitive ovarian cancer with PARP inhibitor maintenance therapy following last platinum-based therapy

A Phase 2 Randomized, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients With Platinum Sensitive Relapsed Epithelial Ovarian Cancer, Who Have Previously Received PARP Inhibitor Maintenance Treatment

AK, CA, CT, FL, GA, KY, LA, MI, MN, NJ, NY, OH, OK, OR, PA, RI, SC, SD, TX, VA, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ceralasertib	AZD6738, ATR kinase inhibitor AZD6738	ATR kinase inhibitor	Clinical Trials
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer

II

Platinum resistant ovarian cancer (must either have received or be ineligible for prior bevacizumab and/or PARP inhibitor)

An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer

MA, NJ

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Afuresertib	GSK2110183	Akt inhibitor	Clinical Trials
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with a NRG1 gene fusion

CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

MI, MO, TN, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Seribantumab	SAR256212, MM-121	ERBB3 antagonist	Clinical Trials

II

Advanced solid tumors with MMR deficiencies (loss of expression of MLH1, MSH2, MSH6 or PMS2), after prior immunotherapy

Phase II Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy

Contact research study staff

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Sirolimus	Rapamycin, Rapamune	mTOR inhibitor	Approved in Other Indications

II

Recurrent rare tumors

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nilotinib	AMN 107, Tasigna	Bcr-abl, c-Kit, and PDGFR kinase inhibitor	Approved in Other Cancers
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

II

Recurrent ovarian cancer with CCND1-3 or CDK4/6 AMP or CDKN2A alterations

An Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial Cancer

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Anastrozole	Arimidex	Aromatase inhibitor
Letrozole	Femara	Aromatase inhibitor	NCCN Guidelines for Ovarian Cancer

II

Advanced HER2+ solid tumors

A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Trastuzumab deruxtecan	T-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201a	ADC: anti-HER2 + topoisomerase I inhibitor (exatecan)	Approved in Other Cancers

II

Advanced solid tumors with atypical BRAF or MEK alterations

A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Contact research study staff

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ulixertinib	BVD-523, ERK inhibitor BVD-523	ERK inhibitor	Clinical Trials

II

Advanced CCR5+ solid tumors - subcutaneous injection of leronlimab with standard-of-care chemotherapy

Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Leronlimab	anti-CCR5 monoclonal antibody PRO 140	Modulates the tumor microenvironment and blocks tumor angiogenesis	Clinical Trials

II

Advanced solid tumors with alterations in BRAF, RAF1, MEK1/2, ERK1/2 or NF1

A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1.

IN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
LY3214996		ERK inhibitor	Clinical Trials

Ib/II

Platinum resistant ovarian cancer or carcinosarcoma

An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors

AL, CA, CO, CT, IL, KS, MA, NJ, NY, OH, OK, PA, RI, TN, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Rebastinib	multitargeted tyrosine kinase inhibitor DCC-2036	Multi-targeted RTK inhibitor	Clinical Trials

Ib/II

Platinum sensitive ovarian cancer

An Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors

CA, IL, IN, KS, NC, OH, TN, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Rebastinib	multitargeted tyrosine kinase inhibitor DCC-2036	Multi-targeted RTK inhibitor	Clinical Trials

Ib/II

Advanced solid tumors with KRAS MUT, KRAS AMP, BRAF non-V600 MUT or NF1 loss of function alterations

A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants With Relapsed/Refractory Solid Tumors and a Phase 1b Study of RMC-4630 With Osimertinib in Participants With EGFR Mutation Positive, Locally Advanced or Metastatic NSCLC

AZ, CA, CO, GA, IL, MD, MA, MI, NC, OH, OK, OR, PA, TN, TX, VA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cobimetinib	XL518, GDC-0973, Cotellic	MEK1 inhibitor	Approved in Other Cancers
RMC-4630	SAR442720	SHP2 inhibitor	Clinical Trials

Ib

Advanced solid tumors (in ovarian expansion)

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Eribulin	B1939 mesylate, E7389, ER-086526, Halaven, halichrondrin B analog	Microtubule destabilizer/mitotic inhibitor	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Selinexor	KPT-330, CRM1 nuclear export inhibitor KPT-330, selective inhibitor of nuclear export KPT-330	Selective inhibition of nuclear export (SINE)	Approved in Other Cancers

Ib

Advanced solid tumors (in ovarian expansion)

Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Trebananib	AMG 386	Angiopoietin 1/2 antagonist	Clinical Trials

Ib

Newly diagnosed, persistent, or recurrent ovarian carcinosarcoma

Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary

OK

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Galunisertib	LY2157299	TGFBR1 antagonist	Clinical Trials
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

Ib

Advanced solid tumors with BRCA1/2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51B/C/D/L mutations (in expansion)

Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Irinotecan	Campothecin-11, Campto, Camptosar	Topoisomerase I inhibitor	NCCN Guidelines for Ovarian Cancer
Rucaparib	AG-014699, PF 01367338, CO-338, Rubraca	PARP inhibitor	Approved in Ovarian Cancer

Ib

Platinum resistant or refractory ovarian cancer (in ovarian expansion)

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b

AL, AZ, CO, FL, GA, MD, MA, MI, NY, OH, OK, OR, PA, SC, TN, TX, UT, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
XMT-1536		ADC: anti-NaPi2b + microtubule destabilizer (auristatin F-HPA)	Clinical Trials

Ib

Platinum resistant ovarian cancer, BRCA1/2 MUT patients must have progressed following PARP inhibitor treatment (inc expansion)

A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Copanlisib	BAY 80-6946, PI3K inhibitor BAY 80-6946	pan-PI3K inhibitor	Approved in Other Cancers
Niraparib	MK4827, Zejula	PARP inhibitor	Approved in Ovarian Cancer

Ib

Platinum sensitive BRCA WT ovarian cancer with ≤ 2 prior platinum therapies (in expansion)

A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian Cancer

AZ, CA, FL, GA, MD, MO, NY, OK, TN, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Cobimetinib	XL518, GDC-0973, Cotellic	MEK1 inhibitor	Approved in Other Cancers
Niraparib	MK4827, Zejula	PARP inhibitor	Approved in Ovarian Cancer

Ib

Platinum sensitive or partially sensitive ovarian cancer with no prior gemcitabine

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors

AZ, CA, LA, NJ, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
TRK-950	monoclonal antibody TRK-950	Undisclosed mechanism	Clinical Trials

I/IIa

Advanced solid tumors

Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors

GA, MA, NJ, NY, PA, SD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
BMS-986218		Blocks CTLA-4 inhibition of T cells	Clinical Trials
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I/IIa

Platinum resistant ovarian cancer

Phase 1/2a Dose Escalation And Expansion Study Evaluating Safety, Tolerability, Pharmacokinetic, Pharmacodynamics And Anti-tumor Activity Of Pf-06873600 As A Single Agent And In Combination With Endocrine Therapy

CA, MA, NY, TN, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
PF-06873600	CDK inhibitor PF-06873600	pan-CDK inhibitor	Clinical Trials

I/IIa

Platinum resistant or refractory mesothelin+ ovarian cancer

A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Who Have Failed Standard Available Therapy

AZ, CA, FL, MN, MO, OH, OK, TN, TX, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
HPN536	HPN536 - a T cell engaging, mesothelin/CD3-specific TriTAC	Re-directs T cells to attack mesothelin+ tumor cells	Clinical Trials

I/IIa

Platinum resistant or refractory ovarian cancer

PHASE 1/2A DOSE ESCALATION, FINDING AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY

MI, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Letrozole	Femara	Aromatase inhibitor	NCCN Guidelines for Ovarian Cancer
Palbociclib	PD-0332991, PD0332991, Ibrance	CDK4/6 inhibitor	Approved in Other Cancers
PF-07104091		CDK2 inhibitor	Clinical Trials

I/II

Recurrent ovarian cancer

Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cediranib	AZD2171, Cediranib maleate, Recentin	VEGFR1-3 kinase inhibitor	Clinical Trials
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer

I/II

Extrapulmonary small cell ovarian cancer

A Phase I/II Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Berzosertib	ATR kinase inhibitor VX-970, VE-822, M6620, VX-970	ATR kinase inhibitor	Clinical Trials
Topotecan	Hycamptamine, Hycamtin, TOPO	Topoisomerase I inhibitor	Approved in Ovarian Cancer

I/II

Platinum resistant or refractory ovarian cancer

Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer

MN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
MV-NIS infected mesynchymal stem cells		Induces immune response and tumor cell lysis	Clinical Trials

I/II

Recurrent, persistent or refractory high grade serous ovarian cancer with BRCA1/2 or HRD or MMR gene alterations or LOH high score

A Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 Mutation

NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer
Tremelimumab	anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab	Blocks CTLA-4 inhibition of T cells	Clinical Trials

I/II

Platinum resistant or refractory ovarian cancer (with peritoneal disease)

A Phase 1/2 Dose Escalation Study With Expansion Cohorts to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

CA, FL, NY, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
ONCOS-102	GM-CSF-encoding oncolytic adenovirus CGTG-102, Ad5/3-D24-GMCSF, CGTG-102	Induces immune response and tumor cell lysis	Clinical Trials

I/II

Recurrent ovarian cancer with Ras pathway alterations or with progression during prior PARP inhibitor treatment

Evaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors With Ras Pathway Alterations, and Ovarian Tumors With PARP Resistance

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer
Selumetinib	AZD6244, ARRY-142886	MEK1/2 inhibitor	Approved in Other Cancers

I/II

Platinum resistant or persistent ovarian cancer

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Defactinib	VS-6063, PF-04554878, PF-04554878	FAK inhibitor	Clinical Trials
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

I/II

Platinum resistant or refractory ovarian cancer with AXL aberations

First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors

AZ, CO, CT, FL, GA, IA, MA, MI, MN, MO, NY, NC, PA, TX, UT, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Enapotamab Vedotin	HuMax-AXL-ADC, anti-AXL monoclonal antibody-MMAE conjugate, anti-AXL/MMAE antibody-drug conjugate	ADC: anti-Axl + microtubule destabilizer (MMAE)	Clinical Trials

I/II

Platinum resistant or refractory ovarian cancer

A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer

MA, NY, OH, OK, TN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cemiplimab	REGN2810, anti-PD-1 monoclonal antibody REGN2810	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
REGN4018	anti-MUC16/CD3 bispecific antibody REGN4018	Re-directs T cells to attack MUC16 (CA125)+ tumor cells	Clinical Trials

I/II

Advanced solid tumors with RET alterations

A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)

AZ, CA, CO, CT, FL, GA, IL, LA, MD, MA, MI, MN, MO, NV, NY, NC, OH, OR, PA, TN, TX, UT, VA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Selpercatinib	RET kinase inhibitor LOXO-292, LOXO-292	RET-kinase inhibitor	Approved in Other Cancers

I/II

Advanced solid tumors

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1

CO, FL, KY, MA, MI, NY, OH, TX, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
ALKS 4230	intermediate-affinity interleukin-2 receptor agonist ALKS 4230	IL-2 receptor agonist	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I/II

Advanced solid cancers

Poly-ICLC (Hiltonol®) Plus Anti-PD1 or Anti-PD-L1 in Unresectable Solid Cancers An Adaptive Phase I/II Clinical Pilot Study

MD, NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Cemiplimab	REGN2810, anti-PD-1 monoclonal antibody REGN2810	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
poly ICLC	poly-ICLC, Hiltonol, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, poly I:poly C with poly-1-lysine stabilizer	Activates dendritic cells and induces interferon production	Clinical Trials

I/II

Recurrent or persistent WT1+ ovarian cancer

A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers

CA, CO, FL, NJ, NY, OH, TX, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Galinpepimut-S	SLS 001, WT-1 analog peptide vaccine SLS-001	Immune response against cancer expressing WT1	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I/II

Advanced solid tumor with high MSI or dMMR - intratumoral injection

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors

AL, AZ, CA, CT, FL, IA, KY, NJ, NY, OR, TN, TX, UT, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
RP1	oncolytic virus RP1, A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus	Induces immune response and tumor cell lysis	Clinical Trials

I/II

Recurrent ovarian cancer

A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Rucaparib in Patients With Advanced Breast, Ovarian, or Prostate Cancer

CA, NJ, PA, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ipatasertib	GDC-0068, Akt Inhibitor GDC-0068, RG7440	pan-AKT inhibitor	Clinical Trials
Rucaparib	AG-014699, PF 01367338, CO-338, Rubraca	PARP inhibitor	Approved in Ovarian Cancer

I/II

Advanced solid tumors

A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer

MA, MI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
LY2880070		Chk1 inhibitor	Clinical Trials

I/II

Platinum resistant or refractory ovarian cancer that is HRD proficient (HRD-)

A Phase I/II Study of Olaparib With Entinostat in the Treatment of Recurrent, Platinum-Refractory or Resistant, Homologous Recombination Repair Proficient Ovarian, Primary Peritoneal, and Fallopian Tube Cancers

TN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Entinostat	HDAC inhibitor SNDX-275, MS 275, SNDX-275	HDAC inhibitor	Clinical Trials
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer

I/II

Platinum resistant or refractory ovarian cancer

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

AZ, CA, CO, CT, DC, FL, GA, IL, KS, KY, LA, MA, MI, MN, MO, NE, NV, NJ, NY, OH, OK, OR, PA, SC, TX, UT, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Cabozantinib	BMS-907351, Cabometyx, XL184, Cometriq	Multi-targeted RTK inhibitor	Approved in Other Cancers

I/II

Platinum resistant or refractory ovarian cancer

Randomized Phase I/II Study of AVB-S6-500 in Combination With Durvalumab (MEDI4736) in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
AVB-S6-500	AVB-500	GAS6 antagonist	Clinical Trials
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers

I/II

Advanced solid tumors

Phase I/II Trial of Ipilimumab or Nivolumab With BMS-986156 and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid Malignancies

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
BMS-986156		GITR (glucocorticoid-induced TNFR) agonist	Clinical Trials
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Radiation Therapy	Radiotherapy, Irradiation

I/II

Advanced solid tumors (in expansion)

A Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Pharmacokinetic Study of IMX-110 in Patients With Advanced Solid Tumors

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
IMX-110	curcumin/doxorubicin-encapsulating nanoparticle IMX-110	NF-kappaB/STAT3/pan-kinase and topoisomerase II inhibition	Clinical Trials

I/II

Platinum resistant or refractory ovarian cancer; BRCA MUT patients must have progressed on PARP inhibitor - intratumoral injection

A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Efficacy Study of mRNA 2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L, for Intratumoral Injection Alone or in Combination With Durvalumab for Patients With Advanced Malignancies

CO, MA, MI, MN, TN, UT

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
mRNA-2416	lipid nanoparticle-encapsulated OX40L mRNA-2416		Clinical Trials

I/II

Advanced solid tumors with prior anti-PD-1/PD-L1 Ab (inc ovarian expansion)

A Dose-optimization, Exploratory Phase Ib/II Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143, When Given in Combination With the Anti-PD-1 Antibody Nivolumab in Patients With Specific Solid Tumors Who Have Progressed During or Immediately After Anti-PD-1/PD-L1 Treatment

FL, IL, MA, MI, MO, NY, OH, PA, TX, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Debio 1143	IAP inhibitor AT-406, AT-406	SMAC mimetic and IAP antagonist	Clinical Trials
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I/II

Platinum resistant or refractory high grade serous FRalpha+ ovarian cancer

A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types

Contact research study staff

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
MORAb-202		ADC: anti-FOLR1 + microtubule destabilizer (eribulin)	Clinical Trials

I/II

Advanced solid tumors with ALK, ROS1 or NTRK1-3 alterations

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

CA, CO, DC, FL, GA, IL, MD, MA, MI, MN, MO, NJ, NY, OH, PA, TX, VA, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Repotrectinib	ALK/ROS1/NTRK/SRC multi-kinase inhibitor TPX-0005, TPX-0005	ALK, ROS1, NTRK1-3, SRC and FAK kinase inhibitor	Clinical Trials

I/II

Advanced solid tumors with oncogenic activation of the NF-κB pathway or amplification of c-IAP1 or c-IAP2

Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

AL, CA, CT, GA, IL, MD, MA, NH, NY, NC, OH, OK, PA, TN, TX, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
ASTX660	XIAP/cIAP1 antagonist ASTX660	IAP antagonist	Clinical Trials

I/II

Advanced solid tumors with MET alterations

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

AZ, CA, DE, FL, MD, MA, MN, MO, NC, OH, SC, TN, WA, WV, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
APL-101	CBT-101, Bozitinib	c-Met kinase inhibitor	Clinical Trials

I/II

Platinum resistant or refractory ovarian cancer (inc expansion)

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients With Solid Tumors Likely to Express NaPi2b

TN, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
XMT-1592		ADC: anti-NaPi2b + microtubule destabilizer (auristatin F-HPA)	Clinical Trials

I/II

Advanced solid tumors with a NRG1 fusion

A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors

AZ, CA, DC, FL, MA, MI, MN, NY, TX, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
MCLA-128	anti-HER2/Anti-HER3 bispecific monoclonal antibody MCLA-128, Zenocutuzumab	Docks on HER2 and blocks NRG-1 mediated growth of tumor cells by binding to HER3	Clinical Trials

I/II

Advanced solid tumors (in ovarian expansion)

A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects With Advanced Solid Tumours

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
FP-1305	anti-Clever-1 mAb, Clevegen	Immune cell stimulation	Clinical Trials